PMID- 24830933
OWN - NLM
STAT- MEDLINE
DCOM- 20150123
LR  - 20140611
IS  - 1873-5967 (Electronic)
IS  - 1386-6532 (Linking)
VI  - 60
IP  - 3
DP  - 2014 Jul
TI  - Predictive factors for adverse dermatological events during pegylated/interferon 
      alpha and ribavirin treatment for hepatitis C.
PG  - 190-5
LID - S1386-6532(14)00145-0 [pii]
LID - 10.1016/j.jcv.2014.04.012 [doi]
AB  - BACKGROUND: Treatment of chronic hepatitis C (CHC) with pegylated 
      interferon-alpha/ribavirin is associated with well-characterized dermatological 
      adverse events (AEs), which can lead to premature discontinuation of treatment. 
      OBJECTIVE: To investigate the incidence and spectrum of dermatological AEs during 
      CHC treatment with interferon-alpha plus ribavirin and analyzed factors 
      predisposing patients to such reactions. STUDY DESIGN: Between January 2008 and 
      December 2012, 152 CHC patients who had received interferon/pegylated interferon 
      plus ribavirin therapy were enrolled in this retrospective study. To determine 
      which factors were associated with dermatological AE development, a Cox 
      proportional-hazards regression analysis was performed. RESULTS: Thirty 
      dermatological AEs were recorded in 28 (18.4%) patients. These reactions included 
      14 (9.2%) patients with eczematous reactions, four (2.6%) patients with xerosis, 
      three (2.0%) patients with new-onset or exacerbation of psoriasis, two (1.3%) 
      patients with lichenoid eruption, two (1.3%) patients with diffuse folliculitis 
      and one patient with lichen planus, alopecia areata, hypermelanosis, and necrosis 
      of the skin and toenails. Application of the Cox proportional-hazards model 
      revealed that age older than 60 years (HR=1.070; 95% CI: 1.043-1.096), 
      pre-existing anaphylaxis/skin disease (HR=2.612; 95% CI: 1.593-3.324), cirrhosis 
      (HR=1.863; 95% CI: 1.047-3.013), and treatment with pegylated interferon 
      formulations (HR=1.930; 95% CI: 1.052-3.687) were associated with occurrence of 
      dermatologic AEs. Twenty-seven (90%) skin conditions were classified as mild to 
      moderate, while one case (3.3%) warranted premature discontinuation of treatment. 
      CONCLUSION: Dermatological AEs resulting from interferon-alpha/ribavirin 
      treatment of CHC contribute to a wide spectrum involve the skin, mucous membrane, 
      hair, and nails. These dermatological AEs correlated with older age, previous 
      skin condition, cirrhosis, and use of pegylated interferon formulations.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Li, Zhengxiao
AU  - Li Z
AD  - Department of Dermatology, The Second Affiliated Hospital, College of Medicine, 
      Xi'an Jiaotong University, PR China.
FAU - Zhang, Yanfei
AU  - Zhang Y
AD  - Department of Dermatology, The Second Affiliated Hospital, College of Medicine, 
      Xi'an Jiaotong University, PR China.
FAU - An, Jingang
AU  - An J
AD  - Department of Dermatology, The Second Affiliated Hospital, College of Medicine, 
      Xi'an Jiaotong University, PR China.
FAU - Feng, Yiguo
AU  - Feng Y
AD  - Department of Dermatology, The Second Affiliated Hospital, College of Medicine, 
      Xi'an Jiaotong University, PR China.
FAU - Deng, Hong
AU  - Deng H
AD  - Department of Infectious Diseases, The Second Affiliated Hospital, College of 
      Medicine, Xi'an Jiaotong University, PR China.
FAU - Xiao, Shengxiang
AU  - Xiao S
AD  - Department of Dermatology, The Second Affiliated Hospital, College of Medicine, 
      Xi'an Jiaotong University, PR China.
FAU - Ji, Fanpu
AU  - Ji F
AD  - Department of Infectious Diseases, The Second Affiliated Hospital, College of 
      Medicine, Xi'an Jiaotong University, PR China. Electronic address: 
      jifanpu1979@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140429
PL  - Netherlands
TA  - J Clin Virol
JT  - Journal of clinical virology : the official publication of the Pan American 
      Society for Clinical Virology
JID - 9815671
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Hepacivirus/genetics
MH  - Hepatitis C/*complications/*drug therapy/virology
MH  - Hepatitis C, Chronic/complications/drug therapy
MH  - Humans
MH  - Interferon-alpha/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Ribavirin/administration & dosage/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Skin Diseases/diagnosis/*etiology
MH  - Treatment Outcome
MH  - Viral Load
MH  - Young Adult
OTO - NOTNLM
OT  - Adverse skin reactions
OT  - Chronic hepatitis C
OT  - Pegylated interferon alpha
OT  - Ribavirin
EDAT- 2014/05/17 06:00
MHDA- 2015/01/24 06:00
CRDT- 2014/05/17 06:00
PHST- 2014/03/19 00:00 [received]
PHST- 2014/04/10 00:00 [revised]
PHST- 2014/04/14 00:00 [accepted]
PHST- 2014/05/17 06:00 [entrez]
PHST- 2014/05/17 06:00 [pubmed]
PHST- 2015/01/24 06:00 [medline]
AID - S1386-6532(14)00145-0 [pii]
AID - 10.1016/j.jcv.2014.04.012 [doi]
PST - ppublish
SO  - J Clin Virol. 2014 Jul;60(3):190-5. doi: 10.1016/j.jcv.2014.04.012. Epub 2014 Apr 
      29.